Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites.
about
Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSAImmunogenicity of the Plasmodium falciparum PfEMP1-VarO Adhesin: Induction of Surface-Reactive and Rosette-Disrupting Antibodies to VarO Infected ErythrocytesDifferential induction of functional IgG using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSAStructural Comparison of Two CSPG-Binding DBL Domains from the VAR2CSA Protein Important in Malaria during PregnancyVar2CSA minimal CSA binding region is located within the N-terminal regionAntigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malariaTowards the rational design of a candidate vaccine against pregnancy associated malaria: conserved sequences of the DBL6epsilon domain of VAR2CSA.Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies.Strain-transcendent immune response to recombinant Var2CSA DBL5-ε domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions.Allelic diversity of the Plasmodium falciparum erythrocyte membrane protein 1 entails variant-specific red cell surface epitopes.Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolatesImmunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes.Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies.Advances and challenges in malaria vaccine development.The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domainsPlasmodium falciparum variability and immune evasion proceed from antigenicity of consensus sequences from DBL6ε; generalization to all DBL from VAR2CSA.Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins.Prospects and Pitfalls of Pregnancy-Associated Malaria Vaccination Based on the Natural Immune Response to Plasmodium falciparum VAR2CSA-Expressing Parasites.Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria.Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian WomenChondroitin sulfate A-adhering Plasmodium falciparum-infected erythrocytes express functionally important antibody epitopes shared by multiple variants.Antibodies to Escherichia coli-expressed C-terminal domains of Plasmodium falciparum variant surface antigen 2-chondroitin sulfate A (VAR2CSA) inhibit binding of CSA-adherent parasites to placental tissue.Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA.Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA.A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples.Statistical prediction of immunity to placental malaria based on multi-assay antibody data for malarial antigens.Down-selection of the VAR2CSA DBL1-2 expressed in as a lead antigen for placental malaria vaccine development
P2860
Q24620671-EA621BCB-1363-4533-9713-D7523DA65127Q27301377-E40FBB9D-61CF-4411-A071-E4513828BDB3Q27349502-748460C3-7AF7-4073-AF0A-9B106CBEB639Q27657099-B58932B3-0835-4BCE-A3A9-0DB92EEAFA35Q28744428-125685BC-FA5A-46FD-A647-E96FA0FED943Q30603697-54D7CC46-3115-4CE8-801A-177DC74B7E08Q33619319-F412BA98-FF0C-46BA-A283-CC9FD21E5F95Q33634689-B90997E5-2024-43C2-B7B6-99A200CFC16EQ33691325-93849F2C-262E-4268-B512-26D27076D785Q33813188-78A3519E-24C7-4368-8A6F-C5CA8E72D40EQ33822296-6058F959-0E43-4B48-BCD3-1AFFFBC14DB5Q33826076-F9F8B63D-46F8-4FCF-A0D3-E49476817DCAQ34095324-F092B4D3-C677-4FA3-88E6-BE058CEEAFCEQ34145333-E22169E1-5FA1-4D18-BCAF-9111415B2FB8Q34170375-C3B5DDF3-3784-45D7-AADA-48067F69D61EQ34571421-52EAD4B9-0083-46A8-AA85-E5BFCE6D9189Q34660001-878C6CB1-F031-4A6F-BD39-0E64F3C46252Q35738477-67290A2E-301B-4E74-80C6-026DE71B0963Q36558721-AEA4FE4C-ADA9-4FFB-8956-4CABBFA75C9DQ36644516-AC40F536-DF2C-477A-8F6F-C7D6F50B6D6CQ36672347-F305B491-C7E3-42FC-B366-99616BD86C73Q36804761-FEBCCB90-C04B-443C-AEEF-D4D2B03BA9F5Q37204480-5467F8DD-599F-43CA-8341-2551DDFF8E31Q37499204-9FC1D552-422E-43CB-B3B2-71D47D78CA32Q40089629-13529B69-5E2C-4BB9-B3A6-EB6DA72977AFQ41992842-7BED94CB-0A35-4654-BF4F-0FFEC0704B19Q56362112-43E4DFC8-B4F3-47A3-8491-316890BFDF3D
P2860
Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Var2CSA DBL6-epsilon domain ex ...... dies to CSA binding parasites.
@en
type
label
Var2CSA DBL6-epsilon domain ex ...... dies to CSA binding parasites.
@en
prefLabel
Var2CSA DBL6-epsilon domain ex ...... dies to CSA binding parasites.
@en
P2093
P2860
P356
P1433
P1476
Var2CSA DBL6-epsilon domain ex ...... odies to CSA binding parasites
@en
P2093
Artur Scherf
Catherine Lépolard
Jürg Gysin
Nicola K Viebig
Pablo Fernandez
P2860
P2888
P356
10.1186/1475-2875-7-170
P577
2008-09-04T00:00:00Z
P5875
P6179
1029333179